TB-500
Regulatory
Legal Status in 2026
No FDA approval for human use in the US; sold only as a research chemical.
This compound has no FDA approval for human use in the United States and is not available through licensed US pharmacies or compounding channels. It has not completed the clinical trials required for FDA approval. It may be sold online as a research chemical without quality controls, purity verification, or dosing standards. Always consult a physician.
About
About TB-500
A synthetic peptide fragment derived from Thymosin Beta-4, this compound functions as an actin-sequestering protein that promotes cell migration, angiogenesis, and tissue repair. Its mechanism involves upregulating cell-building proteins and reducing inflammation at injury sites. Research applications have focused primarily on wound healing, cardiac tissue repair following ischemic injury, and musculoskeletal recovery in preclinical models.
Science
Mechanism of Action
TB-500 sequesters G-actin monomers via its actin-binding domain (LKKTET), reducing free actin availability and promoting F-actin depolymerization. This modulates cell migration, differentiation, and survival. TB-500 also upregulates matrix metalloproteinases, promotes angiogenesis through VEGF receptor signaling, reduces inflammation via downregulation of NF-κB and inflammatory cytokines, and activates stem cell migration to injury sites.
Dosing
Typical Protocol
Loading phase: 2–2.5 mg twice weekly for 4–6 weeks. Maintenance phase: 1–2 mg once weekly for an additional 4–8 weeks. Commonly stacked with BPC-157 for synergistic tissue repair. Administered subcutaneously or intramuscularly.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Availability
Provider availability
TB-500 has no FDA approval for human use and is not available through licensed US prescribing or compounding channels, so Vial does not list providers for it.
Compound comparisons
Compare TB-500
TB-500 set against other compounds people weigh it against.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.